197 related articles for article (PubMed ID: 30850713)
1. Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.
Souchet B; Duchon A; Gu Y; Dairou J; Chevalier C; Daubigney F; Nalesso V; Créau N; Yu Y; Janel N; Herault Y; Delabar JM
Sci Rep; 2019 Mar; 9(1):3914. PubMed ID: 30850713
[TBL] [Abstract][Full Text] [Related]
2. Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
Gu Y; Moroy G; Paul JL; Rebillat AS; Dierssen M; de la Torre R; Cieuta-Walti C; Dairou J; Janel N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092951
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
5. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
6. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
7. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.
Guedj F; Sébrié C; Rivals I; Ledru A; Paly E; Bizot JC; Smith D; Rubin E; Gillet B; Arbones M; Delabar JM
PLoS One; 2009; 4(2):e4606. PubMed ID: 19242551
[TBL] [Abstract][Full Text] [Related]
8. EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model.
Delabar JM; Gomes MAGB; Fructuoso M; Sarrazin N; George N; Fleary-Roberts N; Sun H; Bui LC; Rodrigues-Lima F; Janel N; Dairou J; Maria EJ; Dodd RH; Cariou K; Potier MC
Eur J Med Chem; 2024 Feb; 265():116098. PubMed ID: 38171148
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
10. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
[TBL] [Abstract][Full Text] [Related]
11. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X
Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628
[TBL] [Abstract][Full Text] [Related]
12. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
13. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
14. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.
Thomazeau A; Lassalle O; Iafrati J; Souchet B; Guedj F; Janel N; Chavis P; Delabar J; Manzoni OJ
J Neurosci; 2014 Jan; 34(4):1138-47. PubMed ID: 24453307
[TBL] [Abstract][Full Text] [Related]
15. DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.
De Toma I; Ortega M; Aloy P; Sabidó E; Dierssen M
Front Mol Neurosci; 2019; 12():272. PubMed ID: 31803016
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models.
Souchet B; Guedj F; Penke-Verdier Z; Daubigney F; Duchon A; Herault Y; Bizot JC; Janel N; Créau N; Delatour B; Delabar JM
Front Behav Neurosci; 2015; 9():267. PubMed ID: 26539088
[TBL] [Abstract][Full Text] [Related]
17. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
[TBL] [Abstract][Full Text] [Related]
18. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Blazek JD; Abeysekera I; Li J; Roper RJ
Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
[TBL] [Abstract][Full Text] [Related]
20. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]